These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 12060125)

  • 1. Clinicopathological and prognostic characteristics of CD56-negative multiple myeloma.
    Sahara N; Takeshita A; Shigeno K; Fujisawa S; Takeshita K; Naito K; Ihara M; Ono T; Tamashima S; Nara K; Ohnishi K; Ohno R
    Br J Haematol; 2002 Jun; 117(4):882-5. PubMed ID: 12060125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinicopathological correlates of plasma cell CD56 (NCAM) expression in multiple myeloma.
    Kraj M; Sokołowska U; Kopeć-Szlezak J; Pogłód R; Kruk B; Woźniak J; Szpila T
    Leuk Lymphoma; 2008 Feb; 49(2):298-305. PubMed ID: 18231917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma cells in multiple myeloma express a natural killer cell-associated antigen: CD56 (NKH-1; Leu-19).
    Van Camp B; Durie BG; Spier C; De Waele M; Van Riet I; Vela E; Frutiger Y; Richter L; Grogan TM
    Blood; 1990 Jul; 76(2):377-82. PubMed ID: 1695113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble urokinase-type plasminogen activator receptor (suPAR) as an independent factor predicting worse prognosis and extra-bone marrow involvement in multiple myeloma patients.
    Rigolin GM; Tieghi A; Ciccone M; Bragotti LZ; Cavazzini F; Della Porta M; Castagnari B; Carroccia R; Guerra G; Cuneo A; Castoldi G
    Br J Haematol; 2003 Mar; 120(6):953-9. PubMed ID: 12648064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of surface markers expressed in multiple myeloma: CD56 and other antigens.
    Sahara N; Takeshita A
    Leuk Lymphoma; 2004 Jan; 45(1):61-5. PubMed ID: 15061198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential expression of CD56 and CD44 in the evolution of extramedullary myeloma.
    Dahl IM; Rasmussen T; Kauric G; Husebekk A
    Br J Haematol; 2002 Feb; 116(2):273-7. PubMed ID: 11841427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Soluble CD56 (NCAM): a new differential-diagnostic and prognostic marker in multiple myeloma.
    Kaiser U; Oldenburg M; Jaques G; Auerbach B; Havemann K
    Ann Hematol; 1996 Sep; 73(3):121-6. PubMed ID: 8841099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between intracranial plasmacytoma and multiple myeloma: clinicopathological outcome study.
    Schwartz TH; Rhiew R; Isaacson SR; Orazi A; Bruce JN
    Neurosurgery; 2001 Nov; 49(5):1039-44; discussion 1044-5. PubMed ID: 11846895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD56 expression in multiple myeloma: Correlation with poor prognostic markers but no effect on outcome.
    Koumpis E; Tassi I; Malea T; Papathanasiou K; Papakonstantinou I; Serpanou A; Tsolas E; Kapsali E; Vassilakopoulos TP; Papoudou-Bai A; Hatzimichael E
    Pathol Res Pract; 2021 Sep; 225():153567. PubMed ID: 34352440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathological correlates of CD56 expression in multiple myeloma: a unique entity?
    Mathew P; Ahmann GJ; Witzig TE; Roche PC; Kyle RA; Greipp PR
    Br J Haematol; 1995 Jun; 90(2):459-61. PubMed ID: 7540857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of natural killer-associated antigens in peripheral blood and bone marrow of multiple myeloma patients and prognostic implications.
    García-Sanz R; González M; Orfão A; Moro MJ; Hernández JM; Borrego D; Carnero M; Casanova F; Bárez A; Jiménez R; Portero JA; San Miguel JF
    Br J Haematol; 1996 Apr; 93(1):81-8. PubMed ID: 8611480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prognostic effect of beta 2-microglobulin in multiple myeloma].
    Ortega F; González M; Moro MJ; Gascón A; Duarte I; Martín M; Hernández J; Jiménez-Galindo R; Portero JA; Sanz M
    Med Clin (Barc); 1992 Nov; 99(17):645-8. PubMed ID: 1447935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determination of plasma cell secreting potential as an index of maturity of myelomatous cells and a strong prognostic factor.
    Symeonidis A; Kouraklis-Symeonidis A; Grouzi E; Zolota V; Melachrinou M; Kourea K; Fragopanagou E; Giannakoulas N; Seimeni U; Tiniakou M; Matsouka P; Zoumbos N
    Leuk Lymphoma; 2002 Aug; 43(8):1605-12. PubMed ID: 12400603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distribution of myeloma plasma cells in peripheral blood and bone marrow correlates with CD56 expression.
    Rawstron A; Barrans S; Blythe D; Davies F; English A; Pratt G; Child A; Morgan G; Jack A
    Br J Haematol; 1999 Jan; 104(1):138-43. PubMed ID: 10027726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic relevance of CD56 expression in multiple myeloma: a study including 107 cases treated with high-dose melphalan-based chemotherapy and autologous stem cell transplant.
    Chang H; Samiee S; Yi QL
    Leuk Lymphoma; 2006 Jan; 47(1):43-7. PubMed ID: 16321826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic implications of DNA aneuploidy in 156 untreated multiple myeloma patients. Castelano-Leonés (Spain) Cooperative Group for the Study of Monoclonal Gammopathies.
    García-Sanz R; Orfão A; González M; Moro MJ; Hernández JM; Ortega F; Borrego D; Carnero M; Casanova F; Jiménez R
    Br J Haematol; 1995 May; 90(1):106-12. PubMed ID: 7786771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunophenotypic and genotypic characterisation of multiple myelomas with adverse prognosis characterised by immunohistological expression of the T cell related antigen CD45RO (UCHL-1).
    Menke DM; Horny HP; Griesser H; Atkinson EJ; Kaiserling E; Kyle RA
    J Clin Pathol; 1998 Jun; 51(6):432-7. PubMed ID: 9771441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Relevance of Concordant Expression CD69 and CD56 in Response to Bortezomib Combination Therapy in Multiple Myeloma Patients.
    ElMenshawy N; Farag NA; Atia DM; Abousamra N; Shahin D; Fawzi E; Ghazi H; El-Kott AF; Eissa M
    Cancer Invest; 2021 Oct; 39(9):777-782. PubMed ID: 34344244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD56 Expression Is an Important Prognostic Factor in Multiple Myeloma Even with Bortezomib Induction.
    Skerget M; Skopec B; Zadnik V; Zontar D; Podgornik H; Rebersek K; Furlan T; Cernelc P
    Acta Haematol; 2018; 139(4):228-234. PubMed ID: 29920491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neural cell adhesion molecule expression in plasma cells in bone marrow biopsies and aspirates allows discrimination between multiple myeloma, monoclonal gammopathy of uncertain significance and polyclonal plasmacytosis.
    Martín P; Santón A; Bellas C
    Histopathology; 2004 Apr; 44(4):375-80. PubMed ID: 15049904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.